艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

交易中 02-03 13:19:26 EST

71.50

+0.46

+0.65%

最高71.88	最低70.83	成交量34.66万
今开70.83	昨收71.04	日振幅1.48%
总市值82.18亿	流通市值77.48亿	总股本1.15亿
成交额2,475万	换手率0.32%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":71.5,"timestamp":1770142762925,"preClose":71.04,"halted":0,"volume":346630,"delay":0,"changeRate":0.0064752252252251365,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"交易中","change":0.46,"latestTime":"02-03 13:19:26 EST","open":70.83,"high":71.88,"low":70.83,"amount":24750123.788200002,"amplitude":0.01478,"askPrice":71.54,"askSize":110,"bidPrice":71.5,"bidSize":30,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770152400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.04,"dividendRate":0.042713,"preHourTrading":{"tag":"盘前","latestPrice":71.04,"preClose":71.04,"latestTime":"08:15 EST","volume":48,"amount":3410.7902400000003,"timestamp":1770124541322,"change":0,"changeRate":0,"amplitude":0.000282},"postHourTrading":{"tag":"盘后","latestPrice":71.04,"preClose":71.04,"latestTime":"19:25 EST","volume":19945,"amount":1416896.47,"timestamp":1770078333955,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.554482,"impliedVol":0.281,"impliedVolPercentile":0.9522},"requestUrl":"/m/hq/s/ADC/wiki","defaultTab":"wiki","newsList":[{"id":"1132811598","title":"Pyxis Oncology宣布临时CEO任命及领导层交接，聚焦战略重点与项目延续性","url":"https://stock-news.laohu8.com/highlight/detail?id=1132811598","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132811598?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:49","pubTimestamp":1770119377,"startTime":"0","endTime":"0","summary":"波士顿，2026年2月3日——临床阶段生物制药公司Pyxis Oncology, Inc.今日宣布领导层交接计划，旨在持续推进公司战略与临床目标的执行。自公司首次公开募股以来一直担任董事会成员的Thomas Civik被任命为临时首席执行官，即刻生效。通过此次人事调整，Pyxis Oncology将由深度熟悉公司战略及研发项目的资深领导者掌舵。董事会主席John Flavin表示：\"任命Tom为临时CEO是为了确保领导力的稳健过渡与业务连续性。Pyxis Oncology已奠定坚实的科研与临床基础，我们对核心项目的前景保持乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4139","BK4107","ADC","L","LU2487616109.SGD","BK4231","BK4585","LU0210528500.USD","R","PYXS","BK4022","BK4080","BK4588","BK4232"],"gpt_icon":0},{"id":"1131684922","title":"财报前瞻｜艾格里房产本季度营收预计增18.63%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1131684922","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131684922?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:33","pubTimestamp":1770086001,"startTime":"0","endTime":"0","summary":"艾格里房产将在2026年02月10日发布最新季度财报，市场关注其租金收入增长与利润率表现，以及管理层对净利润和EPS的指引与执行力。市场一致预期显示，本季度艾格里房产总收入预计为1.86亿美元，同比增长18.63%；毛利率预计维持高位但未给出具体预测值；净利润或净利率本季度未形成明确一致预期；调整后每股收益预计为0.47美元，同比增长9.77%；EBIT预计为9,678.30万美元，同比增速26.16%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季度营收预计增18.63%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"gpt_icon":0},{"id":"2606376243","title":"东方证券：IO和ADC为肿瘤头部MNC焦点 联用将迎突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2606376243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606376243?lang=zh_cn&edition=full","pubTime":"2026-01-28 14:13","pubTimestamp":1769580821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，JPM 2026大会上肿瘤领域头部MNC将IO和ADC作为战略重心，且十分重视联合疗法的开发，其中二代IO多来自国产企业，sac-TMT在ADC中地位突出，今年是IO联合ADC确定性提升的关键节点，未来ADC尤其是泛瘤种ADC的需求有望进一步提升。另一方面，围绕IO和ADC的联用探索正全面加速，默沙东已开展9项sac-TMT联用K药的III期临床研究，BMS将推进BNT327与ADC的联用，辉瑞计划今年开展SSGJ-707和ADC联用的III期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1147","ADC","BK0012","BK0276","600958","BK0183","BK0028","BK1564","03958","BK0188","BK4080"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605989254?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PFS","BK4231","ADC","BK4195","BK4211","OS","BK4097","ORR","BK4080"],"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1221951046.USD","BK4585","LU2506952097.USD","PFS","BK4097","LU1221951129.SGD","LU1880398554.USD","LU2506951875.HKD","BK4195","LU1046421795.USD","LU1066051498.USD","LU2506951958.HKD","LU0792757196.USD","LU1244550494.USD","LU1929549753.HKD","BK4231","LU2237443622.USD","LU0868494617.USD","LU1571399168.USD","LU1196500208.SGD","CSCO","ORR","BK4579","OS","ADC","AZN","LU0320765992.SGD","LU2237443895.HKD","IE00BFMHRM44.USD","LU0234572021.USD","LU2237443382.USD","IE000M9KFDE8.USD","BK4560","SG9999001440.SGD","LU1244550577.SGD","SG9999015978.USD","LU1880398471.USD","BK4588","IE00BKVL7J92.USD","BK4527","BK4080","LU1066053197.SGD","BK4612","LU1894683348.USD","LU2417539215.USD","SG9999015945.SGD","LU2237443549.SGD","LU0109394709.USD","LU2247934214.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2605696344","title":"优赫得在华获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2605696344","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605696344?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:46","pubTimestamp":1769071572,"startTime":"0","endTime":"0","summary":"南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得?（英文商品名：Enhertu?，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627420221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2605667194","title":"华福证券：首次覆盖维立志博(09887)给予“买入”评级 下一代IO和ADC疗法全布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2605667194","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605667194?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:38","pubTimestamp":1769067529,"startTime":"0","endTime":"0","summary":"首次覆盖维立志博给予“买入”评级，预计维立志博2025-2027年营业收入分别为1.80、0.94、0.10亿元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","09887","ADC"],"gpt_icon":0},{"id":"2604157635","title":"港股异动 | 映恩生物-B(09606)早盘涨超4% ADAM9靶向ADC癌症新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2604157635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604157635?lang=zh_cn&edition=full","pubTime":"2026-01-20 09:48","pubTimestamp":1768873737,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B早盘涨超4%，截至发稿，涨2.42%，报363.6港元，成交额5105.75万港元。消息面上，1月19日，映恩生物宣布，公司自主研发的ADAM9靶向抗体偶联药物DB-1317已获得国家药监局药品审评中心的新药临床试验批准，同意其单药在晚期/转移性恶性实体瘤患者中开展临床试验。据悉，DB-1317是映恩生物基于公司自主研发的ADC技术平台DITAC开发的新一代ADC产品，具有全球权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","ADC","HK0000500386.USD","09606","LU2543165471.USD","BK4231","HK0000252152.HKD","BK4080"],"gpt_icon":0},{"id":"2603603977","title":"跨国巨头艾伯维锚定本土创新，全球资源如何加速落地中国？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603977","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603977?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:33","pubTimestamp":1768469598,"startTime":"0","endTime":"0","summary":"三生制药将一款处于临床阶段的双特异性抗体药物以60.5亿美元的价格授权给辉瑞；恒瑞医药与葛兰素史克（GSK）达成潜在价值125亿美元的交易；信达生物与武田制药就三款产品达成114亿美元的交易……当下，中国生物医药行业的交易纪录正被本土创新力量持续刷新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620504655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620504655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4585","BK4231","ADC","GSK","BK4532","GSK.UK","BK4007","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2603867929","title":"31亿港元！药明合联拟溢价99%收购东曜药业，ADC产能有望进一步拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603867929","media":"澎湃新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603867929?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:13","pubTimestamp":1768461189,"startTime":"0","endTime":"0","summary":"国内CXO行业再现大手笔收购。1月14日晚间，药明生物（2269.HK）、药明生物附属公司药明合联（2268.HK）及东曜药业（1875.HK）发布联合公告称，药明合联通过财务顾问花旗环球金融亚洲有限公司，向东曜药业发出自愿有条件现金要约，拟收购其全部已发行股份（要约人及一致行动人士已持有或同意收购的股份除外），并注销全部尚未行使购股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620361651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620361651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4231","LU2488822045.USD","SG9999014674.SGD","BK1141","ADC","02268"],"gpt_icon":0},{"id":"2603610556","title":"业绩盈喜, 控股收购东曜药业，药明合联(02268)进一步稳固ADC CDMO市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2603610556","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603610556?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:32","pubTimestamp":1768404738,"startTime":"0","endTime":"0","summary":"同时，通过此次控股收购，药明合联亦希望进一步丰富其项目组合并扩大其客户群，稳固其在 ADC CDMO 领域的领导地位。药明合联早已布局人才梯队建设，截至2025年底，团队规模已突破2600人。截至2025年12月底，药明合联在全球合作客户数量已超过630家，iCMC项目总数达到252个。这一举措不仅能实现产能的本地化交付，更能进一步深化公司在全球生物偶联药CDMO领域的市场覆盖，巩固行业领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1141","BK4231","BK4139","CDMO","LU2488822045.USD","SG9999014674.SGD","02268","ADC"],"gpt_icon":1},{"id":"2603550770","title":"岁末年初，药企高管缘何密集迎人事变动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603550770","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603550770?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:00","pubTimestamp":1768298423,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明离职恒瑞医药（600276.SH）四年多后，周云曙的新任职动态浮出水面。日前，“江苏省肿瘤医院官方平台”发布消息显示，江苏省肿瘤医院（南京医科大学附属肿瘤医院）“江苏省恶性肿瘤先进诊疗重点实验室”与先声药业“神经与肿瘤药物研发全国重点实验室”正式签署战略合作协议，周云曙以“先声药业集团总裁”身份出席。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617514380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617514380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","LU1064130708.USD","LU1655091616.SGD","LU1820825898.SGD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","BK0012","LU2580892789.USD","BK4231","LU1328615791.USD","BK0028","BK0183","LU1997244956.HKD","BK1583","LU2328871848.SGD","BK0239","LU1580142542.USD","LU1997245177.USD","LU1997245094.SGD","01276","LU0359201612.USD","LU1023057109.AUD","BK4080","LU2495084118.USD","BK0196","LU0405327494.USD","LU1969619763.USD","BK0060","LU0359202008.SGD","LU2097828805.USD","LU1781817850.SGD","LU1146622755.USD","LU2148510915.USD","LU1064131003.USD","LU0405327148.USD","LU2289578879.USD","LU2097828631.EUR","BK1574","600276","02096","06978","ADC","LU2097828714.EUR","LU2543165471.USD","LU0359201885.HKD","LU2580892862.HKD","BK1191","BK1161","LU1255011170.USD"],"gpt_icon":0},{"id":"2603539575","title":"港股异动 | 复宏汉霖(02696)再涨超8% 广谱抗肿瘤PD-L1 ADC HLX43末线食管鳞癌II期数据首次发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2603539575","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603539575?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:12","pubTimestamp":1768270333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港元。消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会上，首度公布了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌的II期概念验证数据，本次发布的数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4023","HK0000165453.HKD","LU1169590202.USD","BK4080","02696","HK0000306685.HKD","PD","BK4231","BK1161","LU1169589451.USD","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2601562331","title":"港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601562331?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK1161","02696","HK0000165453.HKD","BK4080","PD","BK4023","BK4231","ADC","LU1169589451.USD"],"gpt_icon":0},{"id":"2601186053","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186053?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:53","pubTimestamp":1767689624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，近日，公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC(注射用iza-bren)被国家药品监督管理局药品审评中心(简称“CDE”)纳入优先审评品种名单。根据公开资料查询，iza-bren也是全球首个被纳入优先审评品种名单的EGFR×HER3双抗ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK4080","BK0239","688506","02615","ADC","91194"],"gpt_icon":0},{"id":"2601020061","title":"科伦博泰生物-B(06990)核心产品TROP2 ADC芦康沙妥珠单抗(SAC-TMT)联合免疫疗法帕博利珠单抗一线治疗PD-L1阳性局部晚期或转移性非小细胞肺癌获NMPA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601020061?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:01","pubTimestamp":1767571299,"startTime":"0","endTime":"0","summary":"此前，公司公布了芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性NSCLC的3期OptiTROP-Lung05临床试验结果，其在主要终点无进展生存期显示出统计学意义和临床意义的显著改善，并在总生存期方面观察到获益趋势。OptiTROP-Lung05研究是首个免疫联合ADC在一线治疗NSCLC上达到主要终点的3期临床研究。此次在一线治疗PD-L1阳性NSCLC获得突破性疗法认定，将为加速芦康沙妥珠单抗在此适应症审评与上市进程提供助力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU1169589451.USD","BK4023","BK4080","ADC","BK4231","LU0196878994.USD","BK1161","06990","LU1169590202.USD"],"gpt_icon":0},{"id":"2600040163","title":"科伦博泰生物-B(06990)：ITGB6 ADC SKB105新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040163","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040163?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:59","pubTimestamp":1767527952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司自主研发的靶向整合素β6抗体偶联药物SKB105的新药临床试验申请已获中国国家药品监督管理局药品审评中心批准，用于治疗晚期实体瘤。公司计划于近期向中国国家药品监督管理局药品审评中心递交SKB118/CR-001的IND申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK4231","ADC","BK4080","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2600056352","title":"港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600056352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600056352?lang=zh_cn&edition=full","pubTime":"2026-01-02 13:43","pubTimestamp":1767332632,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2的抗体药物偶联物——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2495084118.USD","01276","LU1580142542.USD","LU2488822045.USD","LU1146622755.USD","LU0359201612.USD","LU0359202008.SGD","LU1997245094.SGD","LU1997244956.HKD","LU1064130708.USD","LU2097828714.EUR","BK0239","LU1969619763.USD","LU0405327148.USD","LU0359201885.HKD","LU2289578879.USD","LU2580892789.USD","LU2097828805.USD","LU1820825898.SGD","LU1064131003.USD","BK0188","BK4231","LU1255011170.USD","LU1328615791.USD","BK0028","LU2580892862.HKD","LU1781817850.SGD","600276","BK0060","LU2328871848.SGD","LU1655091616.SGD","BK0012","LU1997245177.USD","ADC","BK4080","LU1023057109.AUD","LU2148510915.USD","LU2097828474.EUR","BK0183","LU2543165471.USD","BK1191","LU2097828631.EUR","LU2097828557.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2595588735","title":"健玛生物终止一款在研抗癌疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2595588735","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595588735?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:11","pubTimestamp":1767017460,"startTime":"0","endTime":"0","summary":"丹麦药企健玛生物周一宣布，将终止一款已进入后期临床试验的在研抗体抗癌疗法的研发工作。　　2024 年，百欧恩泰决定不再继续开展该疗法的研究后，健玛生物便独家接手了阿卡萨利单抗的研发及潜在商业化工作。　　健玛生物将把研发资源集中至埃普金利单抗、佩托森他单抗和利纳他巴特 - 塞苏替康等同样处于后期研发阶段的抗癌疗法项目。　　健玛生物补充称，终止阿卡萨利单抗研发的决定，不会影响公司 2025 年全年业绩预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhenrqi0052363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2595784785","title":"新股消息 | 百力司康港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784785","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784785?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:16","pubTimestamp":1767006987,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BlissBio Inc.(简称：百力司康)于6月29日递交的港股招股书满6个月，于12月29日失效，递表时高盛、华泰国际及建银国际为联席保荐人。招股书显示，百力司康是一家处于临床阶段的生物制药公司，致力于开发下一代抗体偶联药物(ADC)，以解决目前肿瘤治疗中重要的未满足的需求。公司核心产品BB-1701(核心产品)是一种人类表皮生长因子受体2(HER2)靶向型艾立布林ADC候选药物，主要针对乳腺癌(BC)、非小细胞肺癌(NSCLC)和潜在的其他HER2表达癌症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4190","ADC","BK4231","BC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.015},{"period":"3month","weight":-0.018},{"period":"6month","weight":-0.0358},{"period":"1year","weight":-0.0211},{"period":"ytd","weight":-0.0137}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.4375,"avgChangeRate":-0.001898},{"month":3,"riseRate":0.580645,"avgChangeRate":0.015289},{"month":4,"riseRate":0.580645,"avgChangeRate":0.002795},{"month":5,"riseRate":0.5,"avgChangeRate":0.015633},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}